Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
55,906,827
-
Share change
-
-281,658
-
Total reported value
-
$663,498,251
-
Put/Call ratio
-
32%
-
Price per share
-
$11.87
-
Number of holders
-
86
-
Value change
-
-$2,398,948
-
Number of buys
-
40
-
Number of sells
-
37
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2018
As of 30 Jun 2018,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
86 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,906,827 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, Capital World Investors, FMR LLC, BAILLIE GIFFORD & CO, WELLINGTON MANAGEMENT GROUP LLP, ORACLE INVESTMENT MANAGEMENT INC, RENAISSANCE TECHNOLOGIES LLC, Tekla Capital Management LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
86
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.